デフォルト表紙
市場調査レポート
商品コード
1236137

白斑治療市場:2030年までの予測

Vitiligo Treatment Market Forecast till 2030

出版日: | 発行: Market Research Future | ページ情報: 英文 122 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.79円
白斑治療市場:2030年までの予測
出版日: 2023年03月07日
発行: Market Research Future
ページ情報: 英文 122 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

白斑治療の市場規模は、調査期間中に6.20%のCAGRで拡大すると予測されています。白斑は、メラノサイトと呼ばれる皮膚の色彩伝達細胞の故障や死滅によってもたらされる皮膚の色素脱失によって描かれる持続的な皮膚疾患です。最近では、様々なスタイル治療に対する消費者の意識の高まり、一人当たりの給与の拡大、コンピュータ化されたステージの受信などから、消費者の間で認知度が大きく上昇しています。

当レポートでは、世界の白斑治療市場について調査し、市場の概要とともに、タイプ別、治療タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第5章 市場要因分析

  • バリューチェーン分析
  • ポーターのファイブフォースモデル
  • COVID-19が白斑治療市場に与える影響

第6章 世界の白斑治療市場、タイプ別

  • 概要
  • 分節性白斑
  • 非分節性白斑

第7章 世界の白斑治療市場、治療タイプ別

  • 概要
  • 治療
  • 手術
  • 投薬

第8章 世界の白斑治療市場、エンドユーザー別

  • 概要
  • 病院
  • 外来診療所
  • その他

第9章 世界の白斑治療市場、地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 概要
  • 競合ベンチマーキング
  • 白斑治療市場における主要な成長戦略
  • 白斑治療市場における開発数の点でトッププレーヤー
  • 主な開発分析
  • 主な発展と成長戦略
  • 主要参入企業の売上分析

第11章 企業プロファイル

  • INCYTE
  • BAUSCH HEALTH COMPANIES INC.
  • KONINKLIJKE PHILIPS N.V.
  • DR. REDDY'S LABORATORIES LTD.
  • STRATA SKIN SCIENCES
  • CLINUVEL PHARMACEUTICALS LTD
  • ISSAR PHARMACEUTICALS PVT. LTD.
  • KERNEL MEDICAL EQUIPMENT CO., LTD.
  • LIGHTSOURCES
  • ROIVANT SCIENCES LTD.

第12章 付録

図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 3 GLOBAL VITILIGO TREATMENT MARKET, FOR SEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4 GLOBAL VITILIGO TREATMENT MARKET, FOR NON-SEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6 GLOBAL VITILIGO TREATMENT MARKET, FOR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7 GLOBAL VITILIGO TREATMENT MARKET, FOR DEPIGMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8 GLOBAL VITILIGO TREATMENT MARKET, FOR LIGHT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9 GLOBAL VITILIGO TREATMENT MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10 GLOBAL VITILIGO TREATMENT MARKET, FOR SKIN GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11 GLOBAL VITILIGO TREATMENT MARKET, FOR BLISTER GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12 GLOBAL VITILIGO TREATMENT MARKET, FOR MICRO-PIGMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13 GLOBAL VITILIGO TREATMENT MARKET, FOR MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14 GLOBAL VITILIGO TREATMENT MARKET, FOR TOPICAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15 GLOBAL VITILIGO TREATMENT MARKET, FOR IMMUNOSUPPRESSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17 GLOBAL VITILIGO TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18 GLOBAL VITILIGO TREATMENT MARKET, FOR AMBULATORY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19 GLOBAL VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28 US: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29 US: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30 US: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31 US: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32 US: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33 US: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34 CANADA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35 CANADA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36 CANADA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37 CANADA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38 CANADA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39 CANADA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40 EUROPE: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41 EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42 EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43 EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44 EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45 EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46 EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47 GERMANY: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48 GERMANY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49 GERMANY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50 GERMANY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51 GERMANY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52 GERMANY: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53 FRANCE: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54 FRANCE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55 FRANCE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56 FRANCE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57 FRANCE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58 FRANCE: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59 UK: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60 UK: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61 UK: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62 UK: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63 UK: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64 UK: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65 ITALY: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66 ITALY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67 ITALY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68 ITALY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69 ITALY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70 ITALY: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71 SPAIN: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72 SPAIN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73 SPAIN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74 SPAIN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75 SPAIN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76 SPAIN: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90 CHINA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91 CHINA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92 CHINA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93 CHINA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94 CHINA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95 CHINA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96 JAPAN: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97 JAPAN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98 JAPAN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99 JAPAN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100 JAPAN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101 JAPAN: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102 INDIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103 INDIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104 INDIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105 INDIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106 INDIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107 INDIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119 AUSTRALIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139 AFRICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140 AFRICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141 AFRICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142 AFRICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143 AFRICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144 AFRICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151 MAJOR MANUFACTURERS IN VITILIGO TREATMENT MARKET
  • TABLE 152 MOST ACTIVE PLAYER IN VITILIGO TREATMENT MARKET
  • TABLE 153 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
  • TABLE 154 MERGERS & ACQUISITIONS
  • TABLE 155 INCYTE: PRODUCTS OFFERED
  • TABLE 156 INCYTE: KEY DEVELOPMENTS
  • TABLE 157 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
  • TABLE 158 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 159 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED
  • TABLE 160 STRATA SKIN SCIENCES: PRODUCTS OFFERED
  • TABLE 161 STRATA SKIN SCIENCES: KEY DEVELOPMENTS
  • TABLE 162 CLINUVEL PHARMACEUTICALS LTD: PRODUCTS OFFERED
  • TABLE 163 ISSAR PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED
  • TABLE 164 KERNEL MEDICAL EQUIPMENT CO., LTD.: PRODUCTS OFFERED
  • TABLE 165 LIGHTSOURCES: PRODUCTS OFFERED
  • TABLE 166 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL VITILIGO TREATMENT MARKET STRUCTURE
  • FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 3 MARKET DYNAMICS: GLOBAL VITILIGO TREATMENT MARKET
  • FIGURE 4 DRIVERS: IMPACT ANALYSIS
  • FIGURE 5 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL VITILIGO TREATMENT MARKET
  • FIGURE 8 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2021 AND 2030 (USD MILLION)
  • FIGURE 9 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2021 AND 2030 (USD MILLION)
  • FIGURE 10 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2021 AND 2030 (USD MILLION)
  • FIGURE 11 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION 2021 AND 2030 (USD MILLION)
  • FIGURE 12 GLOBAL: VITILIGO TREATMENT MARKET SHARE (%), BY REGION, 2021
  • FIGURE 13 NORTH AMERICA: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2021
  • FIGURE 14 EUROPE: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY 2021
  • FIGURE 15 ASIA-PACIFIC: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 16 REST OF THE WORLD: VITILIGO TREATMENT MARKET SHARE (%), BY COUNTRY, 2021
  • FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN VITILIGO TREATMENT MARKET
  • FIGURE 19 GLOBAL VITILIGO TREATMENT MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 20 MAJOR PLAYERS SALES & OPERATING INCOME, 2021
  • FIGURE 21 MAJOR PLAYERS R&D EXPENDITURE, 2021
  • FIGURE 22 INCYTE: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 23 INCYTE: SWOT ANALYSIS
  • FIGURE 24 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS
  • FIGURE 26 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
  • FIGURE 28 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 DR. REDDY'S LABORATORIES LTD.: SWOT ANALYSIS
  • FIGURE 30 STRATA SKIN SCIENCES: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 CLINUVEL PHARMACEUTICALS LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 CLINUVEL PHARMACEUTICALS LTD: SWOT ANALYSIS
  • FIGURE 33 ROIVANT SCIENCES LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED
目次
Product Code: MRFR/HC/6970-CR

Vitiligo Treatment Market research report Forecast till 2030

Market Overview

The Vitiligo Treatment Market is projected to register a CAGR of 6.20% during the review period. Vitiligo is a persistent dermatological problem portrayed by skin depigmentation brought about by the failing or demise of the skin's color-delivering cells known as melanocytes. Accordingly, distinct white patches show up on the skin. The circumstances endure, making bigger areas of skin lose color. Treatment might further develop skin appearance yet doesn't fix the illness. The key factors that drive the worldwide vitiligo treatment market are the developing significance of tasteful allure and mindfulness and the rising commonness of vitiligo cases. the advancement of innovation proposing treatments for treating various difficulties brought about by the confusion, and the pervasiveness of speculations by government bodies in medical care foundation speeds up the market development.

Lately, there is a huge ascent in excellence cognizance among customers inferable from the developing mindfulness among shoppers about various style treatments, expanding per capita pay, and reception of computerized stages. As per the Global Society of Stylish Plastic Medical procedure (ISAPS), there was a 27.3% development in overall complete non-surgeries somewhere in the range between 2015 and 2019. Furthermore, as indicated by the American Culture of Plastic Specialists (ASPS), the quantity of negligibly intrusive tasteful systems saw about a 200% expansion during 2000-2017. Besides, around 15.9 million negligibly obtrusive restorative methods were acted in 2018, which was a 2% ascent in contrast with 2017. Subsequently, the rising geriatric populace additionally drives the interest in negligibly obtrusive restorative methodology.

Segment Overview

By Type, the vitiligo treatment market is divided into Segmental vitiligo and non-segmental vitiligo. By Treatment Type, the market is classified into Surgery, Therapy, and Medication.

By the End-User industry, the market is divided into Ambulatory Clinics, Hospitals, and Others.

Regional Analysis

North America ruled the worldwide vitiligo treatment market in 2021, owing to the presence of repayment exercises and the developing significance of tasteful allure likewise adding to regional market development.

As per the article distributed in the Diary of the European Foundation of Dermatology and Venereology (JEADV), the online-populace-based study exhibited that the commonness of vitiligo was 1.3% in Europe. Additionally, mechanical progressions in vitiligo treatment strategies are being taken on in the region because of the number of individuals languishing.

The vitiligo treatment market in Asia-Pacific is driven by an expansion in the number of innovative work exercises and developing interest in vitiligo treatment choices. For example, as indicated by the Indian Dermatology Online Diary (IDOJ), a cross-sectional review was led among 200 patients with vitiligo, the review expresses that 16.5% of people had segmental vitiligo, while 83.5% had non-segmental vitiligo. Besides, the ascent in the number of drives embraced by different public and confidential associations as acquisitions, joint efforts, administrative endorsements, and interests in this region is helping the market development.

Major Players

Incyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Reddy's Laboratories Ltd. (India), STRATA Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd. (India), Kernel Medical Equipment Co., LTD. (China), and LightSource (US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 OVERVIEW
    • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA MINING
  • 3.3 SECONDARY RESEARCH
  • 3.4 PRIMARY RESEARCH
    • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS
    • 4.2.2 INCREASING PREVALENCE OF VITLIGO
  • 4.3 RESTRAINTS
    • 4.3.1 LACK OF TRAINED PROFESSIONALS
  • 4.4 OPPORTUNITIES
    • 4.4.1 RISING NUMBER OF CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON REGION
    • 5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 SEGMENTAL VITILIGO
  • 6.3 NON-SEGMENTAL VITILIGO

7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE

  • 7.1 OVERVIEW
  • 7.2 THERAPY
    • 7.2.1 DEPIGMENTATION
    • 7.2.2 LIGHT
  • 7.3 SURGERY
    • 7.3.1 SKIN GRAFTING
    • 7.3.2 BLISTER GRAFTING
    • 7.3.3 MICRO-PIGMENTATION
  • 7.4 MEDICATION
    • 7.4.1 TOPICAL CORTICOSTEROIDS
    • 7.4.2 IMMUNOSUPPRESSIVE

8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS
  • 8.3 AMBULATORY CLINICS
  • 8.4 OTHERS

9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 FRANCE
    • 9.3.3 UK
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 JAPAN
    • 9.4.3 INDIA
    • 9.4.4 SOUTH KOREA
    • 9.4.5 AUSTRALIA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET
  • 10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET
  • 10.5 KEY DEVELOPMENT ANALYSIS
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
    • 10.6.2 MERGERS & ACQUISITIONS
  • 10.7 MAJOR PLAYERS SALES ANALYSIS
    • 10.7.1 SALES & OPERATING INCOME, 2021
    • 10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2021

11 COMPANY PROFILE

  • 11.1 INCYTE
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 BAUSCH HEALTH COMPANIES INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 KONINKLIJKE PHILIPS N.V.
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 DR. REDDY'S LABORATORIES LTD.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 STRATA SKIN SCIENCES
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 CLINUVEL PHARMACEUTICALS LTD
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 ISSAR PHARMACEUTICALS PVT. LTD.
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL ANALYSIS
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.
    • 11.8.1 COMPANY OVERVIEWS
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 LIGHTSOURCES
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL ANALYSIS
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 ROIVANT SCIENCES LTD.
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL ANALYSIS
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 PRODUCTS OFFERED
    • 11.10.6 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS